Recent studies provide real-world evidence supporting the benefits of polyethylene glycol loxenatide combined with basal insulin for type 2 diabetes management, as well as oral semaglutide's role in improving glycemic control. These developments represent meaningful progress in treatment options, aiming for simpler regimens and better patient adherence in diabetes care globally.